MBX Biosciences, Inc. Share Price
MBXMBX Biosciences, Inc. Stock Performance
Open $24.93 | Prev. Close $24.64 | Circuit Range N/A |
Day Range $24.47 - $25.53 | Year Range $4.81 - $26.13 | Volume 19,868 |
Average Traded $24.78 |
MBX Biosciences, Inc. Share Price Chart
About MBX Biosciences, Inc.
MBX Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of precision peptide therapies for the treatment of endocrine and metabolic disorders. Its lead product candidate is MBX 2109, a parathyroid hormone peptide prodrug, which is in Phase 2 clinical trial for the treatment of chronic hypoparathyroidism. The company is also developing MBX 1416, a long-acting glucagon-like peptide-1 (GLP-1) receptor antagonist that is in Phase 1 clinical trial a potential therapy for post-bariatric hypoglycemia, a chronic complication of bariatric surgery. In addition, it is developing MBX 4291, a lead obesity product candidate, which is in investigational new drug-enabling studies for the treatment of obesity and co-morbidities. The company was founded in 2018 and is based in Carmel, Indiana.
MBX Biosciences, Inc. Historical Data
| Day | Open | Close | Change % |
|---|---|---|---|
12-Nov-25 | $24.93 | $24.79 | +0.00% |
12-Nov-25 | $24.93 | $24.79 | -0.52% |
11-Nov-25 | $24.38 | $24.91 | +2.07% |
10-Nov-25 | $26.13 | $24.41 | -4.56% |
07-Nov-25 | $23.05 | $25.57 | +3.38% |
06-Nov-25 | $23.02 | $24.74 | +9.69% |
05-Nov-25 | $20.88 | $22.55 | +9.12% |